Reducing Costs Of Depression In The USA

17 March 1997

The direct and indirect costs of depression in the USA are put as highas $43.7 billion a year, with an estimated patient population of around 15 million. However, says a new study from Datamonitor, available through the Marketletter's offices, the actual economic effect of depression is much greater, due to the high number of undiagnosed or misdiagnosed people who constitute a large proportion of the indirect costs.

The cost of treating depression is comparatively low (see table); it costs around $22.3 billion less to treat than AIDS, despite the high prevalence of depression compared to AIDS cases. Datamonitor calls for greater emphasis on diagnosing and treating depression to prevent indirect costs escalating as the prevalence rises.

Comparison of total estimated economic costs of depression and three other conditions Condition/syndrome Total estimated cost ($bn) ----------------------------------------------- Stroke 18.0

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight